Immune Tolerance Induction Study

NCT00701701 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Study was conducted to fulfill a post marketing commitment (PMC 6). FDA acknowledged fulfillment of PMC.

Conditions

Pompe Disease
Glycogen Storage Disease Type II (GSD-II)
Glycogenesis 2 Acid Maltase Deficiency

Interventions

BIOLOGICAL: Myozyme® (alglucosidase alfa)
BIOLOGICAL: Myozyme® (alglucosidase alfa)

Sponsor

Genzyme, a Sanofi Company